Cencora Inc banner

Cencora Inc
NYSE:COR

Watchlist Manager
Cencora Inc Logo
Cencora Inc
NYSE:COR
Watchlist
Price: 311.99 USD 0.59% Market Closed
Market Cap: $60.7B

Cencora Inc
Current Portion of Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Cencora Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Cencora Inc
NYSE:COR
Current Portion of Long-Term Debt
$342.3m
CAGR 3-Years
-30%
CAGR 5-Years
42%
CAGR 10-Years
12%
Cardinal Health Inc
NYSE:CAH
Current Portion of Long-Term Debt
$680m
CAGR 3-Years
6%
CAGR 5-Years
121%
CAGR 10-Years
7%
Henry Schein Inc
NASDAQ:HSIC
Current Portion of Long-Term Debt
$33m
CAGR 3-Years
77%
CAGR 5-Years
-21%
CAGR 10-Years
7%
Adapthealth Corp
NASDAQ:AHCO
Current Portion of Long-Term Debt
$38m
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Patterson Companies Inc
NASDAQ:PDCO
Current Portion of Long-Term Debt
$126.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mckesson Corp
NYSE:MCK
Current Portion of Long-Term Debt
$1.1B
CAGR 3-Years
41%
CAGR 5-Years
8%
CAGR 10-Years
1%
No Stocks Found

Cencora Inc
Glance View

Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.

COR Intrinsic Value
534.94 USD
Undervaluation 42%
Intrinsic Value
Price $311.99

See Also

What is Cencora Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
342.3m USD

Based on the financial report for Dec 31, 2025, Cencora Inc's Current Portion of Long-Term Debt amounts to 342.3m USD.

What is Cencora Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
12%

Over the last year, the Current Portion of Long-Term Debt growth was -85%. The average annual Current Portion of Long-Term Debt growth rates for Cencora Inc have been -30% over the past three years , 42% over the past five years , and 12% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett